Compare Redwire Corporation (RDW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Redwire Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Redwire Corporation trades at $10.74 (market cap $2.81B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 47.7× Redwire Corporation's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| RDW | VRTX | |
|---|---|---|
Market Cap | $2.81B | $134.06B |
Sector | Technology | Health |
52-Week High | $25.90 | $557.96 |
52-Week Low | $5.06 | $376.62 |
Enterprise Value | $2.34B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Redwire Corporation (RDW) trades at $11.23, up 6.65% today, with a bullish technical signal and strong analyst support. The stock shows improving revenue trends with 2026 projections reaching $426 million, though profitability remains challenged with negative margins. Recent news highlights strategic investments in phased-array technology and record backlog growth, while institutional interest is strong with BlackRock's $196.5 million position.
The outlook remains cautiously optimistic given 80% analyst buy ratings and a $12.17 price target, but significant risks persist including continued cash burn, execution challenges, and premium valuation. Investors face the tension between promising space/defense growth opportunities and the company's ongoing inability to achieve profitability despite revenue expansion.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
